These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24335195)

  • 41. Association of hypoxia-inducible factor-1 alpha gene polymorphism with renal cell carcinoma susceptibility.
    Huang L; Li MQ; Ou C; Huang WC; Liu JF; Huang H
    J Cancer Res Ther; 2018 Dec; 14(Supplement):S1105-S1109. PubMed ID: 30539853
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients.
    Fransén K; Fenech M; Fredrikson M; Dabrosin C; Söderkvist P
    Mol Carcinog; 2006 Nov; 45(11):833-40. PubMed ID: 16865676
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression.
    Chang YC; Chan YC; Chang WM; Lin YF; Yang CJ; Su CY; Huang MS; Wu ATH; Hsiao M
    Cancer Lett; 2017 Sep; 403():28-36. PubMed ID: 28610954
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The association of genetic polymorphisms of hypoxia inducible factor-1 alpha and vascular endothelial growth factor with increased risk of chronic obstructive pulmonary disease: A case-control study.
    Yu ZG; Wang BZ; Cheng ZZ
    Kaohsiung J Med Sci; 2017 Sep; 33(9):433-441. PubMed ID: 28865600
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
    Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
    Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
    Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
    [TBL] [Abstract][Full Text] [Related]  

  • 47. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes.
    Wang X; Ren H; Zhao T; Ma W; Dong J; Zhang S; Xin W; Yang S; Jia L; Hao J
    Oncotarget; 2016 Mar; 7(12):13717-29. PubMed ID: 26872370
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
    Galván-Femenía I; Guindo M; Duran X; Calabuig-Fariñas S; Mercader JM; Ramirez JL; Rosell R; Torrents D; Carreras A; Kohno T; Jantus-Lewintre E; Camps C; Perucho M; Sumoy L; Yokota J; de Cid R
    Cancer Treat Res Commun; 2018; 15():21-31. PubMed ID: 30207284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
    Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
    [TBL] [Abstract][Full Text] [Related]  

  • 51. VEGF single nucleotide polymorphisms predict improved outcome in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Qi H; Zhang W; Wang Y; Ge M; Wang T; Zhang L; Zhong M; Shi X; Liang X; Zhan Q; Li Q
    J Chemother; 2023 Feb; 35(1):53-62. PubMed ID: 35262460
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between HIF-1 Alpha Gene Polymorphisms and Response in Patients Undergoing Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer.
    Chen Q; Tian WJ; Huang ML; Liu CH; Yao TT; Guan MM
    Med Sci Monit; 2016 Sep; 22():3140-6. PubMed ID: 27593081
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M; Giovannetti E; Tibaldi C; Camerini A; Di Costanzo F; Barbieri F; Burgers JA; Vincent A; Peters GJ; Smit EF; Ardizzoni A
    Lung Cancer; 2012 Oct; 78(1):92-9. PubMed ID: 22889494
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Heat shock protein 70 as a predictive marker for platinum-based adjuvant chemotherapy in patients with resected non-small cell lung cancer.
    Park TS; Kim HR; Koh JS; Jang SH; Hwang YI; Yoon HI; Chung JH; Kim CH; Kim SS; Kim WS; Jo J; Lee JC; Choi CM
    Lung Cancer; 2014 Nov; 86(2):262-7. PubMed ID: 25261232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
    Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
    Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y; Huang ZY; Yu HF; Luo LH
    Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):859-63. PubMed ID: 21223694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association between single nucleotide polymorphisms (SNPs) and toxicity of advanced non-small-cell lung cancer patients treated with chemotherapy.
    Zhang L; Gao G; Li X; Ren S; Li A; Xu J; Zhang J; Zhou C
    PLoS One; 2012; 7(10):e48350. PubMed ID: 23118991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. HIF-1α P582S and A588T polymorphisms and digestive system cancer risk-a meta-analysis.
    Yang X; Zhang C; Zhu HC; Qin Q; Zhao LJ; Liu J; Xu LP; Zhang Q; Cai J; Ma JX; Cheng HY; Sun XC
    Tumour Biol; 2014 Mar; 35(3):2825-30. PubMed ID: 24293391
    [TBL] [Abstract][Full Text] [Related]  

  • 59. No association of the hypoxia-inducible factor-1α gene polymorphisms with survival in patients with colorectal cancer.
    Lee SJ; Kim JG; Sohn SK; Chae YS; Moon JH; Kang BW; Park JS; Park JY; Choi GS
    Med Oncol; 2011 Dec; 28(4):1032-7. PubMed ID: 20635169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FGFR4 genetic polymorphisms determine the chemotherapy response of Chinese patients with non-small cell lung cancer.
    Fang HM; Tian G; Zhou LJ; Zhou HY; Fang YZ
    Acta Pharmacol Sin; 2013 Apr; 34(4):549-54. PubMed ID: 23524567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.